Misdosing Incident Prompts Astellas To Change Muscle Relaxant Succin Name
This article was originally published in PharmAsia News
Executive SummaryA death caused by drug misdosing in Japan has prompted Astellas to change the name for muscle relaxant Succin (suxamethonium) injection. Last November, a patient died after a hospital in Tokushima Prefecture mistakenly administrated Succin to the patient, who was originally prescribed antibacterial Saxizon (hydrocortisone sodium succinate) by Kowa Pharmaceutical. The incident prompted Japan's Ministry of Health, Labor and Welfare to put out a notice to Astellas and nationwide medical facilities. Astellas will now market the drug with its generic name. (Click here for more - Japanese language
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.